Lumos Pharma, Inc. Common Stock
LUMO
LUMO was delisted on the 11th of December, 2024.
104 hedge funds and large institutions have $202M invested in Lumos Pharma, Inc. Common Stock in 2016 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 31 increasing their positions, 38 reducing their positions, and 12 closing their positions.
228% more call options, than puts
Call options by funds: $19.1M | Put options by funds: $5.81M
13% more capital invested
Capital invested by funds: $178M → $202M (+$24M)
7% less funds holding
Funds holding: 112 → 104 (-8)
18% less repeat investments, than reductions
Existing positions increased: 31 | Existing positions reduced: 38
67% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 12
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
+$3.94M |
| 2 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
+$1.29M |
| 3 |
CCI
Columbus Circle Investors
|
+$1.2M |
| 4 |
PP
PDT Partners
New York
|
+$865K |
| 5 |
HT
HAP Trading
New York
|
+$775K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$5.92M |
| 2 |
Renaissance Technologies
New York
|
-$5.17M |
| 3 |
BIM
Bogle Investment Management
Newton Lower Falls,
Massachusetts
|
-$2.65M |
| 4 |
TAM
Tiverton Asset Management
Wilimington,
Delaware
|
-$1.73M |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$1.09M |
LUMO Hedge Fund Activity: Q3 2016 in Review
104 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Lumos Pharma, Inc. Common Stock (LUMO) for Q3 2016, worth a combined $202M — up 13% from $178M a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of LUMO and 4 opened new positions — a net loss of 8 holders — while 38 trimmed existing stakes and 31 added.
The largest buyer was OrbiMed, adding an estimated $3.94M. The largest seller was Fidelity Investments, cutting an estimated $5.92M.
- 104 institutional investors held Lumos Pharma, Inc. Common Stock (LUMO) as of Q3 2016, down from 112 in Q2 2016.
- Funds reported $202M of Lumos Pharma, Inc. Common Stock stock for Q3 2016, up 13% quarter-over-quarter.
- 4 funds opened new Lumos Pharma, Inc. Common Stock positions in Q3 2016 and 12 closed out, a net change of -8 holders.
- The largest Lumos Pharma, Inc. Common Stock buyer in Q3 2016 was OrbiMed, an estimated $3.94M added.
- The largest Lumos Pharma, Inc. Common Stock seller in Q3 2016 was Fidelity Investments, an estimated $5.92M sold.
Based on aggregated 13F filings for Q3 2016.